A Clinical Comparison of Calculated versus Direct Measurement of Low-Density Lipoprotein Cholesterol Level

Pharmacotherapy

Volumn 24, Issue 2 I, 2004, Pages 167-172

  Lindsey, Cameron C ^a   Graham, Maqual R ^a   Johnston, Thomas P ^a   Kiroff, Chelsea G ^a   Freshley, Anna ^a  

^a NONE

Author keywords

Cholesterol; Friedewald formula; Low density lipoprotein cholesterol

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY MASS; CALCULATION; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED STATES;

AGED; BLOOD CHEMICAL ANALYSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DECISION SUPPORT TECHNIQUES; DEMOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 1142298600     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.2.167.33142     Document Type: Article

References (21)

1. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002;48:236-54.
2. Hirany S, Li D, Jialal I. A more valid measurement of low-density lipoprotein cholesterol in diabetic patients. Am J Med 1997;102:48-53.
3. Marniemi J, Maki J, Maatela J, Jarvisalo J, Impivaara O. Poor applicability of the Friedewald formula in the assessment of serum LDL cholesterol for clinical purposes. Clin Biochem 1995;28:285-9.
4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001;285(19):2486-97.
6. Esteban-Salan M. Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients. Clin Chem 2000;46(8):1121-31.
7. National Heart, Lung and Blood Institute, National Institutes of Diabetes and Digestive and Kidney Disease. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. NIH publication no. 98-4083. Bethesda, MD: National Institutes of Health, 1998.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
9. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-75.
11. Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21-7.
12. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
13. Jones P, Kafonek S, Lauroa I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
14. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
15. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.
16. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
17. Otvos JD, Elias JJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002:90(suppl):22i-9.
18. Faas FH, Earleywine A, Smith WG, Simmons DL. How should low-density lipoprotein cholesterol concentration be determined? J Fam Pract 2002;51(11):972-5.
19. Rubies-Prat J, Reverter JL, Senti M, et al. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993;16(8):1081-6.
20. Branchi A, Rovellini A, Sommariva D, Torri A. Accuracy of calculated serum low-density lipoprotein cholesterol for the assessment of coronary heart disease risk in NIDDM patients. Diabetes Care 1998;21:1397-401.
21. Wang TY, Haddad M, Wang TS. Low triglyceride levels affect calculation of low-density lipoprotein cholesterol values. Arch Pathol Lab Med 2001;125:404-5.